Results
cancers, GI cancers, liver cancers, 1076 pancreatic cancers, CRC, cancer, esophageal cancers, Cancer
ESOPHAGEAL CANCER, CANCERS, GASTRIC CANCERS, LIVER CANCER, CANCER, CANCER
Of 154 887 participants enrolled in the PLCO Cancer Screening Trial, 135 161 (median [range] age, 62 [55-78] years; 8726 [6.5%] Asian, Hispanic, or Pacific Islander; 6920 [5.1%] non-Hispanic Black; 119 453 [88.4%] non-Hispanic White; 62 [0.1%] missing race; 67 643 [50.0%] female and 67 518 [50.0%] male) were included in the analysis. The mean (SD) follow-up time of the eligible cohort was 13.9 (6.0) years, and the median (range) was 14.9 (0-24.2) years. During follow-up, 34 946 (25.9%) were diagnosed with cancer, with 5088 (14.6%) GI cancers. A total of 2803 (55.1%) of the incident GI cancers were CRC, with 376 esophageal cancers (7.4%), 485 gastric cancers (9.5%), 348 liver cancers (6.8%), and 1076 pancreatic cancers (21.1%). The demographic characteristics of the analyzed cohort are included in 